country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-182091

Copy Link Print Information

CYD-1-79

CYD-1-79 is a selective positive allosteric modulator of 5-HT2C receptor. CYD-1-79 potentiates 5-HT-evoked intracellular calcium release via a topographically distinct allosteric site. CYD-1-79 shows significant inhibition of binding at dopamine D3 receptor, DAT, and α2A/α2B adrenergic receptors. CYD-1-79 modulates 5-HT2C receptor-mediated spontaneous ambulation in rodents and synergizes with a low dose of a 5-HT2C receptor agonist. CYD-1-79 attenuates relapse vulnerability of psychoactive substance in a rodent self-administration model. CYD-1-79 can be used for the research of neurological disease.

For research use only. We do not sell to patients.

CAS No.: 2220235-94-7
Formula: C₂₀H₄₀N₂O₃
Molecular Weight:356.54

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

CYD-1-79 Chemical Structure

CAS No.: 2220235-94-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

5-HT_2C Receptor

D₃ Receptor

Alpha-2A adrenergic receptor

Alpha-2B adrenergic receptor

All 5-HT Receptor Isoforms :

All Dopamine Receptor Isoforms :

All Adrenergic Receptor Isoforms :

All Calcium Channel Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	E_max	123.2 % Compound: 16	Positive allosteric modulation of human 5-HT2CR expressed in CHO cells assessed as 5-HT-induced intracellular calcium release at 1 nM preincubated for 15 mins followed by 5-HT addition by calcium-4 dye based FLIPR assay (Rvb = 100%) Positive allosteric modulation of human 5-HT2CR expressed in CHO cells assessed as 5-HT-induced intracellular calcium release at 1 nM preincubated for 15 mins followed by 5-HT addition by calcium-4 dye based FLIPR assay (Rvb = 100%)	[PMID: 29620897]
CHO	E_max	123.2 % Compound: 3; CYD-1-79	Positive allosteric modulation of human 5HT2CR expressed in CHO cells assessed as increase in 5-HT induced intracellular calcium release at 1 nM preincubated for 15 mins followed by 5-HT addition and measured at 1 secs interval for 360 secs by calcium 4 d Positive allosteric modulation of human 5HT2CR expressed in CHO cells assessed as increase in 5-HT induced intracellular calcium release at 1 nM preincubated for 15 mins followed by 5-HT addition and measured at 1 secs interval for 360 secs by calcium 4 d	[PMID: 32567857]

In Vitro

CYD-1-79 (Compound 16) (1 pM-1 μM; 15 min) promotes an upward shift of 5-HT-evoked Cai2+ release at multiple
concentrations without a leftward shift^[1].
CYD-1-79 (1 pM-1 μM; 15 min) does not modulate 5-HT₂A receptor-mediated intracellular calcium release in h5-HT₂A R-CHO cells, demonstrating subtype selectivity for 5-HT₂C receptors^[1].
CYD-1-79 (10 μM) does not significantly bind to orthosteric sites of 5-HT receptor subtypes, including 5-HT₂C, but shows significant inhibition of binding at dopamine D₃ receptor, DAT, and α₂A/α₂B adrenergic receptors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	T_1/2	T_max	C_max	AUC_0-inf	F	CL	V_ss
Rat^[1]	5 mg/kg	i.v.	6.59 ± 0.26 h	/	/	939 ± 108 ng·h/mL	/	5.37 ± 0.61 L/h/kg	35.07 ± 4.66 L/kg
Rat^[1]	10 mg/kg	p.o.	5.82 ± 0.37 h	3.3 ± 0.58 h	68.1 ± 6.8 ng/mL	737 ± 56 ng·h/mL	39.1 %	/	/

In Vivo

CYD-1-79 (Compound 16) (0.5-5 mg/kg; i.p.; single dose) significantly suppresses spontaneous ambulatory and vertical locomotor activity in male Sprague-Dawley rats within the first 30 minutes post-administration at the 5 mg/kg dose, while lower doses show no significant effects^[1].
CYD-1-79 (5 mg/kg; i.p.; single dose) allosterically potentiates the locomotor-suppressant effects of the 5-HT2C agonist WAY163909 (HY-15401) in male Sprague-Dawley rats, an effect mediated by 5-HT2C receptor activation^[1].
CYD-1-79 (0.125-1 mg/kg; i.p.; single dose) partially substitutes for the discriminative stimulus effects of the 5-HT2C agonist WAY163909 when administered alone, but synergizes with a low dose of WAY163909 (0.5 mg/kg) to produce full substitution for its discriminative stimulus effects in trained male Sprague-Dawley rats^[1].
CYD-1-79 (compound 16) (1 mg/kg; i.p.; single dose) significantly suppresses psychoactive substance cue reactivity in male Sprague-Dawley rats trained to self-administer psychoactive substance^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague-Dawley (male, 225-325 g)^[1]
Dosage:

0.5 mg/kg; 1 mg/kg; 5 mg/kg
Administration:

i.p.; single dose
Result:

Significantly reduced mean total ambulations and mean total vertical activity (±SEM) compared to saline at 5 mg/kg (p < 0.05).
Did not produce statistically significant changes in ambulations or vertical activity relative to saline at 0.5 mg/kg and 1 mg/kg.

Animal Model:

Sprague-Dawley (male, 250-275 g, trained to self-administer psychoactive substance)^[1]
Dosage:

1 mg/kg
Administration:

i.p.; single dose
Result:

Significantly reduced presses on the previously active lever during the 60-minute cue-reinforced component compared to vehicle (p < 0.05, with significant differences observed at multiple 5-minute time points).
Did not significantly alter inactive lever presses relative to vehicle.

Chemical Information

CAS No. 2220235-94-7
Molecular Weight 356.54
Formula C₂₀H₄₀N₂O₃
SMILES

O=C([C@H]1NCC[C@@H](CCCCCCCCCCC)C1)NCC(O)CO
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Wild CT, et al. Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT_2C Receptor. J Med Chem. 2019;62(1):288-305. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

100 mg

Get Quote In-stock

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

CYD-1-79

All 5-HT Receptor Isoforms

All Dopamine Receptor Isoforms

All Adrenergic Receptor Isoforms

All Calcium Channel Isoforms

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

CYD-1-79 Related Classifications

HY-182091 Related Classifications